Celgene and Acceleron Pharma are preparing to file their experimental myelodysplastic syndromes (MDS) therapy on both sides of the Atlantic on the back of promising data from a late-stage study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback